NCT03514017 2026-03-02Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Terminated5 enrolled 11 charts
NCT06863402 2025-12-23Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRoswell Park Cancer InstitutePhase 2 Recruiting32 enrolled
NCT03035331 2025-05-16Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaMayo ClinicPhase 1/2 Completed11 enrolled 12 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02332980 2024-01-03Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasMayo ClinicPhase 2 Completed65 enrolled 21 charts